Q2 EPS Forecast for Eli Lilly and Company Cut by Analyst

Eli Lilly and Company (NYSE:LLY - Free Report) - Leerink Partnrs dropped their Q2 2025 earnings estimates for Eli Lilly and Company in a research note issued to investors on Thursday, July 10th. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings of $5.40 per share for the quarter, down from their prior estimate of $5.54. The consensus estimate for Eli Lilly and Company's current full-year earnings is $23.48 per share. Leerink Partnrs also issued estimates for Eli Lilly and Company's FY2025 earnings at $21.35 EPS.

A number of other equities research analysts have also issued reports on the company. Morgan Stanley reaffirmed an "overweight" rating and issued a $1,135.00 target price (up previously from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. Wells Fargo & Company reissued an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Erste Group Bank lowered shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. Wall Street Zen lowered shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Saturday, June 28th. Finally, HSBC lowered shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and cut their price objective for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. One research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of "Moderate Buy" and a consensus target price of $1,012.56.

Eli Lilly and Company Price Performance

LLY stock traded down $27.76 on Monday, reaching $762.04. The company had a trading volume of 4,100,206 shares, compared to its average volume of 3,682,082. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. The company's fifty day moving average is $766.32 and its 200 day moving average is $799.83. The company has a market cap of $722.21 billion, a P/E ratio of 62.00, a PEG ratio of 1.15 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The business had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. During the same quarter in the previous year, the firm posted $2.58 EPS. The business's revenue was up 45.2% on a year-over-year basis.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be given a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.79%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's payout ratio is currently 48.82%.

Institutional Investors Weigh In On Eli Lilly and Company

Several large investors have recently made changes to their positions in the business. Chicago Capital LLC increased its position in shares of Eli Lilly and Company by 6.8% in the second quarter. Chicago Capital LLC now owns 91,438 shares of the company's stock worth $71,279,000 after acquiring an additional 5,807 shares in the last quarter. Trivium Point Advisory LLC increased its position in shares of Eli Lilly and Company by 3.2% in the second quarter. Trivium Point Advisory LLC now owns 2,966 shares of the company's stock worth $2,312,000 after acquiring an additional 93 shares in the last quarter. Emerald Advisors LLC increased its position in shares of Eli Lilly and Company by 60.8% in the second quarter. Emerald Advisors LLC now owns 1,021 shares of the company's stock worth $796,000 after acquiring an additional 386 shares in the last quarter. Bluesphere Advisors LLC increased its position in shares of Eli Lilly and Company by 29.1% in the second quarter. Bluesphere Advisors LLC now owns 1,550 shares of the company's stock worth $1,209,000 after acquiring an additional 349 shares in the last quarter. Finally, DiNuzzo Private Wealth Inc. increased its position in shares of Eli Lilly and Company by 6.5% in the second quarter. DiNuzzo Private Wealth Inc. now owns 395 shares of the company's stock worth $308,000 after acquiring an additional 24 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.